Brimonidine 0.2% Ophthalmic Solution (5 ml)
Licensed U.S. Pharmacy | Pharmacy Verified

Brimonidine 0.2% Ophthalmic Solution (5 ml)

Item# MWI060301
FREE SHIPPING Over $39! * Pet Food & Other Exclusions
QTY:-+
$5.99$7.99
In-Stock & Ready to Ship
Recurring Saings in EprxAUTOSHIP & SAVE[Details]

Related Items

  • Description
  • Directions
  • Reviews

Description

Brimonidine is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist.

Prescription Required

Directions

View Brimonidine Drug Facts Sheet.

The recommended dose is one drop of Brimonidine tartrate ophthalmic solution, 0.2% in the affected eye(s) three times daily, approximately 8 hours apart.

Brimonidine tartrate ophthalmic solution, 0.2% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.

OVERDOSAGE

No information is available on overdosage in humans. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.

INDICATIONS AND USAGE

Brimonidine tartrate ophthalmic solution, 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution, 0.2% diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.

CONTRAINDICATIONS

Brimonidine tartrate ophthalmic solution, 0.2% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.